Mirtazapine in Alzheimer-associated Weight Loss

NCT01505504 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2012-01-06

No results posted yet for this study

Summary

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.

The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Conditions

Interventions

DRUG

mirtazapine

30 mg at bedtime

Sponsors & Collaborators

  • Brugmann University Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01505504 on ClinicalTrials.gov